Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe
April 01 2019 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced the appointment of Gianluca
Corbinelli as Chief Commercial Officer - Europe, reporting to
Thomas Mitro, Aerie’s President and Chief Operating Officer. Mr.
Corbinelli will be responsible for overseeing the execution of all
aspects of Aerie’s commercialization activities in Europe, to
develop the commercial infrastructure necessary to support Aerie’s
business plans in Europe including ultimately the successful
commercialization of products in the region upon their
approval.
Mr. Corbinelli recently held related leadership positions at
Shire International AG and Bayer AG. He brings significant
experience in international commercialization strategy and
execution, particularly in ophthalmology markets.
“Europe represents the second largest glaucoma market after the
U.S. and has always been an important component of our strategy. We
have had an active presence in Europe since before we initiated our
Mercury 3 trial for Rocklatan™ (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, which commenced in September of
2017. Since then, our Mercury 3 trial has been ongoing, our
regulatory filing for Rhokiinsa®, known as Rhopressa® (netarsudil
ophthalmic solution) 0.02% in the U.S., has been accepted for
review by the European authorities, and we have continued to build
our presence at various ophthalmology congresses in Europe. The
interest in our product candidates is notably increasing across the
region,” said Vicente Anido, Jr., Ph.D., Chairman and Chief
Executive Officer.”
Dr. Anido continued, “We are now at a point where we need
focused senior leadership as we prepare to ultimately enter this
critical market. We believe Gianluca brings the perfect background
for this new position, including broad international strategy,
marketing, commercialization and business expertise, with
significant leadership experience in the European region and
ophthalmology markets. We wish him great success in this exciting
role.”
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
retinal diseases and other diseases of the eye. Aerie's first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eyedrop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United
States in April 2018. In clinical trials of Rhopressa®,
the most common adverse reactions were conjunctival hyperemia,
corneal verticillata, instillation site pain, and conjunctival
hemorrhage. More information about Rhopressa®, including the
product label, is available at www.rhopressa.com. Aerie’s
second product for the reduction of elevated intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension,
Rocklatan™ (netarsudil and latanoprost ophthalmic solution)
0.02%/0.005%, the first and only fixed-dose combination of
Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost,
has been approved by the FDA and is expected to be
launched in the United States in the second quarter of 2019.
In clinical trials of Rocklatan™, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan™, including the product label, is
available at www.rocklatan.com. Aerie continues to focus on
global expansion and the development of additional product
candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the commercialization and manufacturing of Rhopressa® and
Rocklatan™ or any future product candidates, including the timing,
cost or other aspects of the commercial launch of Rhopressa® and
Rocklatan™ or any future product candidates; our commercialization,
marketing, manufacturing and supply management capabilities and
strategies; the success, timing and cost of our ongoing and
anticipated preclinical studies and clinical trials for Rhopressa®
and Rocklatan™, with respect to regulatory approval outside of the
United States or additional indications, and any future product
candidates, including statements regarding the timing of initiation
and completion of the studies and trials; the timing of and our
ability to request, obtain and maintain FDA or other regulatory
authority approval of, or other action with respect to, as
applicable, Rhopressa®, Rocklatan™ or any future product
candidates, including the expected timing of, and timing of
regulatory and/or other review of, filings for, as applicable,
Rhopressa®, Rocklatan™ or any future product candidates; the
potential advantages of Rhopressa® and Rocklatan™ or any future
product candidates; our plans to pursue development of additional
product candidates and technologies within and beyond
ophthalmology; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma, including development of our
retina program; our ability to protect our proprietary technology
and enforce our intellectual property rights; and our expectations
regarding strategic operations, including our ability to in-license
or acquire additional ophthalmic products, product candidates or
technologies. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). FDA approval of Rhopressa® and
Rocklatan™ also do not constitute regulatory approval of Rhopressa®
and Rocklatan™ in jurisdictions outside the United States and there
can be no assurance that we will receive regulatory approval for
Rhopressa® and Rocklatan™ in jurisdictions outside the United
States. Forward-looking statements are not guarantees of future
performance and our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking
statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190401005071/en/
Media: Tad Heitmann 949-526-8747;
theitmann@aeriepharma.comInvestors: Ami Bavishi 908-947-3949;
abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024